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Pituitary adenoma (PA) is a common intracranial neoplasm that impacts on human health 
through interfering hypothalamus–pituitary–target organ axis systems. The development 
of proteomics gives great promises in the clarification of molecular mechanisms of a PA 
and discovery of effective biomarkers for prediction, prevention, early-stage diagnosis, 
and treatment for a PA. A great progress in the field of PA proteomics has been made in 
the past 10 years, including (i) the use of laser-capture microdissection, (ii) proteomics 
analyses of functional PAs (such as prolactinoma), invasive and non-invasive non- 
functional pituitary adenomas (NFPAs), protein post-translational modifications such 
as phosphorylation and tyrosine nitration, NFPA heterogeneity, and hormone isoforms, 
(iii) the use of protein antibody array, (iv) serum proteomics and peptidomics, (v) the 
integration of proteomics and other omics data, and (vi) the proposal of multi-parameter 
systematic strategy for a PA. This review will summarize these progresses of proteomics 
in PAs, point out the existing drawbacks, propose the future research directions, and 
address the clinical relevance of PA proteomics data, in order to achieve our long-term 
goal that is use of proteomics to clarify molecular mechanisms, construct molecular 
networks, and discover effective biomarkers.
Keywords: pituitary adenoma, proteome, heterogeneity, reference map, two-dimensional gel electrophoresis, 
mass spectrometry, bioinformatics
Abbreviations: 2D, two-dimension; 2DGE, two-dimensional gel electrophoresis; ACTH, adrenocorticotropic hormone; 
CSF, cerebrospinal fluid; DEG, differentially expressed gene; DEP, differentially expressed protein; FPA, functional pituitary 
adenoma; FSH, follicle-stimulating hormone; GH, growth hormone; IEF, isoelectric focusing; IL1, interleukin 1; IMAC, 
immobilized metal ion affinity chromatography; IPA, ingenuity pathway analysis; LC, liquid chromatography; LCM, 
laser-capture microdissection; LH, luteinizing hormone; MALDI, matrix-assisted laser desorption ionization; MDLC, 
multi-dimensional liquid chromatography; MGT, multiple gel-based technologies; MS/MS, tandem mass spectrometry; MS, 
mass spectrometry; NFPA, non-functional pituitary adenoma; NTAC, nitrotyrosine affinity column; PA, pituitary adenoma; 
PKA, cAMP-dependent protein kinase; PPPM, predictive, preventive and personalized medicine; PRL, prolactin; PTM, post-
translational modification; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; SELDI, surface-enhanced 
laser desorption/ionization; TOF, time-of-flight; TSH, thyrotropin-stimulating hormone or thyrotropin.
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iNTRODUCTiON
The pituitary gland, which is located in the bottom-middle of 
cranial cavity, functions in many biological processes. Pituitary 
is the most important endocrine gland of body and is composed 
of several kinds of cells, including corticotroph, thyrotroph, 
somatotroph, lactotroph, and gonadotroph, which is responsible 
for the secretion of corresponding hormone to regulate the 
endocrine system (1, 2). The endocrine functions are affected if 
any of the pituitary cell types goes wrong. Pituitary adenoma (PA) 
is the common neoplasm in pituitary gland and accounts for ca. 
10% in intracranial tumors (3–5). Although most of the PAs are 
benign, its invasive features do exist and always comes with poor 
prognosis (6). The different types of PAs have different origin of 
cells and involve different endogenous and exogenous factors, 
which cause PA highly heterogeneous (3). PAs are clinically 
classified into functional and non-functional pituitary adenomas 
(FPAs and NFPAs). FPAs, commonly refer to monoclonal, origi-
nate from adrenocorticotropic hormone (ACTH) cell adenoma, 
thyrotropin-stimulating hormone (TSH) cell adenoma, growth 
hormone (GH) cell adenoma, and prolactin (PRL) cell adenoma, 
whereas the NFPAs commonly originate from gonadotroph cells 
(2, 7). NFPAs are subclassified into intact luteinizing hormone 
(LH+), follicle-stimulating hormone (FSH+), LH/FSH+, null cell, 
oncocytoma, silent corticotroph, and silent somatotroph subtypes 
(2). These differences in pathophysiological characteristics are 
the  basis of proteomic heterogeneity in PAs. A series of proteom-
ics strategies have been extensively used to study PAs, and the 
status and perspectives regarding PA proteomics were reviewed 
in detail by Zhan and Desiderio in the year 2004 (1). After that, 
significant progresses have been made in PA proteomics in the 
past 10 years, including sample preparation using laser-capture 
microdissection (LCM) (8, 9), proteomics analyses of FPA (such 
as prolactinoma) (10), invasive versus non-invasive PAs (6, 11), 
NFPA subtypes (12), serum (13, 14), protein variants/isoforms 
(3, 10, 15, 16), post-translational modifications (PTMs) (17–21), 
and protein molecular networks (22). This article reviews these 
progresses in PA proteomics in the past 10  years, the existing 
drawbacks, future perspectives, and the clinical relevance of PA 
proteomics data.
PROGReSSeS iN PA PROTeOMiCS
Sample Preparation Using Laser-Capture 
Microdissection Coupled with Two-
dimensional Liquid Chromatography
Two obvious drawbacks exist in two-dimensional gel electro-
phoresis (2DGE)-based quantitative comparison of proteomes 
between PAs and controls (1, 23). First, a PA tissue is commonly 
obtained from neurosurgery operation, and pituitary control 
tissue is commonly obtained from postmortem tissues died from 
other diseases or accidents. The origin of cells in PA is monoclonal, 
which is originated from corticotroph, somatotroph, thyrotroph, 
lactotroph, and gonadotroph in the pituitary gland (1). Thus, 
a PA tissue sample contains a relatively pure cell type, whereas 
postmortem pituitary control tissue sample contains multiple cell 
types, including corticotroph, somatotroph, thyrotroph, lacto-
troph, gonadotroph, and other types of cells. These differences in 
cell types affect the accurate comparison between PA and control 
tissue proteomes. Second, 2DGE with pH 3–10 IPG strip and 
12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) gel in separation of proteome is limited within a 
range of proteins with pH 4–8 and mass 15–150 kDa. These pro-
teins with pI < 4 or pI > 8 and Mr > 150 kDa or Mr < 10 kDa are 
usually lost, which seriously impacts on the comparison between 
PA and control proteomes. Moreover, 2DGE has difficulty in the 
detection of low-abundance proteins in a proteome, which are 
usually associated with important physiological and pathological 
processes.
In order to overcome these drawbacks, LCM (24, 25) and multi-
dimensional liquid chromatography (MDLC) (26) were used to 
analyze PA proteomes (8, 9, 27, 28). LCM can isolate, purify, and 
enrich tumor cells from PA tissues and the corresponding pituitary 
cells from control pituitaries, such as corticotroph, somatotroph, 
thyrotroph, lactotroph, and gonadotroph. This approach resolves 
the inconsistency in the origin of cells between PA and control 
pituitaries and achieves the accurate comparison between PA and 
control proteomes. Compared to 2DGE, MDLC has significant 
advantages in maximizing the coverage of a proteome because 
it is not to be limited in the detection and identification of low-
abundance proteins, extremely acidic/basic proteins, extremely 
low/high-mass proteins, and hydrophobic proteins (26).
An FPA prolactinoma was analyzed using LCM and MDLC 
(8, 9, 27, 28). Prolactinoma tissue contains multiple cells, includ-
ing lactotroph tumor cells, endothelial cells, fibroblasts, and other 
stromal cells (8). The lactotroph tumor cells were isolated and 
purified using immunohistochemistry-guided LCM (27, 28), and 
a total of 2243 unique proteins from LCM-enriched lactotroph 
tumor cells were identified using SDS-PAGE and 2D-LC-tandem 
mass spectrometry (MS/MS) (8), which form currently the 
biggest protein database for prolactinoma proteome. Moreover, 
immuno-LCM was used to enrich lactotroph cells from postmor-
tem human pituitary tissues (9). A total of 1660 proteins from 
LCM-enriched lactotroph cells were identified using 2D-LC–MS/
MS, which represent currently the biggest proteomic database 
of normal lactotroph cells. However, currently, no quantitative 
comparison study was carried out between LCM-enriched lacto-
troph tumor and normal cells to discover accurate differentially 
expressed proteins (DEPs) for the clarification of prolactinoma 
tumorigenesis.
Significant extension of Proteomic 
Reference Mapping Data in PAs and 
Controls
Large-scale proteomic reference mapping data are essential to 
discover PA-related proteins for the understanding of molecu-
lar mechanisms and discovery of reliable biomarkers of a PA. 
(i) For a human pituitary proteome, a total of 1449 proteins 
were identified using multiple gel-based technology (MGT), 
including in-gel isoelectric focusing (IEF)–LC–MS/MS and 
SDS-PAGE–LC–MS/MS (29). Most of these proteins distribute 
within the range of pI 3.8–12.0 (75%) and Mr 20–100 kDa (70%), 
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and lots of low-abundance proteins were identified, including 55 
protein kinases (PKAs), 45 receptors, 29 transcription factors, 
and 43 Ras-family proteins such as 11 G proteins. Currently, 
these data form the biggest protein reference map of a human 
pituitary proteome. (ii) For an NFPA proteome, 2DGE-based 
proteomics technique was used to identify 111 unique proteins 
in an NFPA tissue (30) and 107 unique proteins in an FSH+-
NFPA (31), which forms the protein reference map to serve 
for 2DGE-based comparative proteomics analysis of NFPAs. 
Furthermore, the proteomic reference map of FSH+-NFPA 
contains 107 unique proteins that were involved in multiple 
functional systems, including receptor signal pathways, tran-
scription and translation regulating system, bioenzyme system, 
oxidative stress, glutathione metabolism, gap junction, and 
inflammation signaling pathway, which provide a reference 
to in-depth analysis of the heterogeneity of NFPA proteomes 
(31). (iii) For a prolactinoma proteome, immno-LCM in 
combination with 2D-LC–MS/MS was used to identify 2243 
proteins from LCM-purified lactotroph tumor cells (8) and 
1660 proteins from LCM-purified normal lactotroph cells (9); 
these data form the biggest proteomic database for purified 
lactotroph tumor cells and normal cells and benefit to analyze 
prolactinoma tumorigenesis. Moreover, 305 proteins were 
identified in LCM-purified normal lactotroph cells (9) and 
whole pituitary control tissues (29). These extended proteomic 
reference data will benefit analysis of different subtypes of FPA 
and NFPA proteomes to discover reliable biomarkers for the 
understanding of molecular mechanisms, early-stage diagno-
sis, and therapeutic targets.
Proteomics Analysis of invasive 
Characteristics of NFPAs
Most of the PAs are benign. However, microscopic evidence 
shows that approximately 40% and even up to 80% of PAs have 
local invasion to surrounding structures (32–35), which causes 
difficulty in complete removal of a tumor through neurosurgery, 
increases the risks of complications and poor therapeutic out-
come, and results in a need of adjuvant radiotherapy or medica-
tion after neurosurgery. Therefore, the invasive characteristics of 
PAs are a challenging clinical problem. Clarification of molecular 
mechanisms and discovery of protein biomarkers regarding 
invasiveness of PAs are necessary to better manage an invasive 
PA patient (36). Quantitative transcriptomics study revealed 346 
differentially expressed genes (DEGs) (233 upregulated and 113 
downregulated) in invasive relative to non-invasive NFPAs (36). 
A 2DGE-based comparative proteomics discovered 30 DEPs 
between invasive and non-invasive PAs (11). Furthermore, 2DGE 
proteomic comparison between 4 invasive and 4 non-invasive 
NFPAs (6) identified 57 DEPs (30 upregulated and 27 down-
regulated) from 103 differential 2D gel spots (64 upregulated 
and 39 downregulated), and these DEPs were involved in several 
invasiveness-related pathway networks, including oxidative 
stress, mitochondrial dysfunction, MAPK-signaling abnormal-
ity, ketogenesis and ketolysis, TR/RXR activation, proteolysis 
abnormality, CDK5 signaling abnormality, and amyloid process-
ing. These findings provide important clues to insight into the 
molecular mechanisms of invasiveness of an NFPA and discovery 
of reliable protein biomarkers to guide adjuvant treatment for 
post-neurosurgery invasive NFPAs.
Proteomics Analysis of Heterogeneity 
of NFPAs
Non-functional pituitary adenoma is a highly heterogeneous 
neoplasm with different origin of cells and multiple hormone-
expressed subtypes, including intact gonadotroph with LH/FSH+ 
(40–79%), silent somatotroph with GH expression (3%), silent 
corticotroph with ACTH expression (8%), null cell without 
hormone expression (17%), and oncocytoma without hormone 
expression (6%) (3, 37, 38). The intact gonadotroph may lead to 
several hormone-expressed subtypes of NFPAs, including LH+, 
FSH+, or LH/FSH+. The interesting thing is that silent hormone 
expression associates the invasiveness of an NFPA. For example, 
ACTH+-NFPA was more invasive and had higher recurrence rate 
than ACTH−-NFPA (39). The imbalance of ERα and ERβ expres-
sions is involved in the pathological process and tumor biological 
behavior, such as invasiveness of an NFPA (40), and the ERα/
ERβ ratio was positively related to invasive degree of an NFPA. 
Thereby, it is necessary to investigate proteomic heterogeneity 
among NFPA subtypes to discover the common and specific 
biomarkers for the accurate understanding of molecular mecha-
nisms, early-stage diagnosis, and prognostic assessment and the 
therapeutic targets toward personalized and precise medicine. 
2DGE-based comparative proteomics was used to identify 76 
DEPs in NF−, LH+, FSH+, and LH/FSH+ (NF− means NFPA that 
had negative immunohistochemical stains for LH, FSH, ACTH, 
GH, PRL, and TSH) relative to pituitary controls (12). Of them, 
44 DEPs (10 upregulated and 34 downregulated) were common 
to these 4 NFPA subtypes. The rest of DEPs were common or spe-
cific to some of the four NFPA subtypes. Four pathway–network 
systems, including mitochondrial dysfunction, oxidative stress, 
MAPK-signaling abnormality, and cell-cycle dysregulation, were 
common to four NFPA subtypes. However, many differences 
existed in each pathway–network system among four NFPA 
subtypes, including different expression levels of each protein 
node, different protein profiles, and different pathway–network 
profiles (12). These data provided a heterogeneous profile of 
human NFPA proteomes that would benefit in-depth clarifica-
tion of NFPA heterogeneity, molecular mechanisms of NFPAs, 
and discovery of effective biomarkers for early-stage diagnosis, 
therapy, and prognosis for NFPA personalized and precise 
medicine practice.
Proteomics Analysis of Protein  
variants/isoforms and PTMs of PAs
The process of a gene-coded protein involves multiple post- 
transcriptional/post-translational regulations, including splic-
ing, modifications, translocation, and spatial conformation 
(41–43). Protein variants/isoforms are mainly derived from 
splicing and PTMs. Protein variants/isoforms and PTMs are 
very important aspects in a proteome because they function in 
multiple physiological and pathological processes and would be 
biomarkers and therapeutic targets (44). Currently, exploration 
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of protein variants/isoforms and PTMs is much insufficient in 
the width and depth in a PA proteome. By far, GH (or PRL) 
variants/isoforms in a human pituitary proteome have been 
documented (3, 10, 15, 16). PTMs regarding phosphorylation 
and nitration in PA and control proteomes have been reported 
(17–21).
Growth hormone is a very important hormone in the body. 
Abnormal secretions of GH are associated with many GH-related 
diseases, such as dwarfism, gigantism, acromegalia, and adenoma. 
The synthesis and release of human GH (hGH) are regulated 
under a series of factors (15). The hGH/IGF1 axis plays an impor-
tant role in stimulating body growth (45), whereas some PTMs, 
such as phosphorylation, involve signal transduction pathway 
of hGH/IGF1 axis (46). Four hGH isoforms have been found in 
some GH-producing adenomas. Study (47) demonstrates that 
extensively molecular heterogeneity existed in hGH because of 
alternative splicing, different PTMs, and proteolytic processing 
and that circulating hGH composites of various proportions 
among three non-22-kDa GH isoforms 2–4 in various GH-related 
diseases. 2DGE-based proteomics found that 24 2D gel spots 
contained hGH, with significantly different expression propor-
tions of these isoforms, namely, isoform 1 (87.5%) >  isoform 2 
(8.1%) >  isoform 3 (3.3%) >  isoform 4 (1.1%) (15). Moreover, 
three phosphorylation sites (Ser-77, Ser-176, and Ser-132) and 
a deamidation at Asn-178 were identified in the hGH amino 
acid sequence. Also, many studies demonstrate the ratio of non-
22 kDa GH isoform might be a marker for normal and abnormal 
growth (48), and the evaluation of these GH isoforms could be a 
clinical monitoring for acromegalic patients (49). A 2DGE-based 
comparative proteomics (21) found at least 17 GH isoforms and 
6 PRL isoforms in human pituitary proteomes, and not all these 
GH and PRL isoforms were associated with PAs.
Phosphorylation in a protein is an important PTM, which is 
involved in the regulation of multiple critical biological functions, 
such as protein–molecule (DNA, RNA, and protein) interac-
tions, enzyme activity, protein trafficking, protein intracellular 
localization, and protein degradation, and is extensively associ-
ated with different diseases, such as cancer, inflammation, and 
neurodegenerative diseases (17). Phosphorylation occurs in Ser, 
Thr, and Tyr residues in a protein and is dynamically and revers-
ibly regulated with PKAs and phosphatases that are the common 
drug targets, and much attention has been paid to protein phos-
phorylation event (50). Protein phosphorylation analysis was 
carried out in pituitary control tissues, which identified a total of 
28 phosphoproteins from 2 different studies (17, 18), including 
8 phosphorylation sites in 6 pituitary phosphoproteins that were 
characterized using immobilized metal ion affinity chromatog-
raphy (IMAC)-based LC–MS/MS from unseparated digested 
pituitary protein mixture (18) and 50 phosphorylation sites in 26 
pituitary phosphoproteins (73 phosphopeptides) that were char-
acterized using a modified strategy-in-gel IEF–LC–MS/MS from 
digested pituitary protein mixture (17). These data expanded 
human pituitary phosphoprotein database. However, quantitative 
phosphoproteomics has not been performed between PAs and 
controls to discover PA-related phosphoproteins and phospho-
sites for in-depth understanding of biological significance of 
phosphorylation in PAs.
Tyrosine nitration in a protein is another important PTM 
that is mainly derived from in  vivo peroxynitrite (ONOO−) 
pathway, myeloperoxidase pathway, and metalloperoxidase 
reaction pathway (19, 51, 52). Nitration decreases the electron 
density of a phenolic ring of tyrosine residue to affect the 
affinity ability between protein–protein interactions, such as 
enzyme–substrate, receptor–ligand, and antigen–antibody, 
and is extensively associated with different pathophysiologi-
cal processes, such as cancer, neurodegenerative disease, and 
inflammation (19). Nitroproteomics was performed in pituitary 
controls (20, 53) and adenomas (21). Eight nitroproteins and 
eight nitrotyrosine sites were characterized from a pituitary 
control tissue using 2DGE-based nitrotyrosine Western blot 
coupled with MS/MS (20, 53), including cGMP-dependent 
PKA 2, stanniocalcin 1, synaptosomal-associated protein, actin, 
immunoglobulin α Fc receptor, mitochondrial co-chaperone 
protein HscB, progestin and adipoQ receptor family member 
III, and proteasome subunit α type 2. Nine nitroproteins and 
10 nitrotyrosine sites were characterized from a PA tissue using 
nitrotyrosine affinity column (NATC)-based MALDI–MS/MS 
(21), including sphingosine-1-phosphate lyase 1, zinc finger 
protein 432, cAMP-dependent PKA type I-β regulatory subunit, 
Rho-GTPase-activating protein 5, leukocyte immunoglobulin-
like receptor subfamily A member 4, centaurin-β 1, proteasome 
subunit α type 2 interleukin 1 family member 6, and rhophilin 
2. Moreover, three nitroprotein–protein complexes were identi-
fied, including nitrated proteasome–ubiquitin complex, nitrated 
β-subunit of cAMP-dependent PKA complex, and nitrated inter-
leukin 1 family member 6-interleukin 1 receptor– interleukin 
1 receptor-associated kinase-like 2 (IL1F6–IL1R–IRAK2) (21). 
Moreover, protein domain/motif analysis found that most 
nitrotyrosine sites occurred within important protein domains 
and motifs (21), and pathway–network analysis found that these 
nitroproteins function in important signaling pathway-network 
systems (22), which demonstrated that tyrosine nitration might 
play important roles in the formation of a human PA. However, 
quantitative nitroproteomics has not been performed between 
PAs and controls to discover PA-related nitroproteins and 
nitrotyrosine sites for in-depth understanding of biological 
significance of tyrosine nitration in PAs.
Serum Proteomics and Peptidomics 
in NFPAs
No biomarker is used to early diagnose an NFPA, and NFPA is 
usually diagnosed exclusively using CT or MRI after appearance 
of compression symptoms or sometimes by chance (13). Serum 
is an important window to predict, early diagnose, and prognosis 
assess a PA. One study (13) analyzed 34 sera from NFPA patients 
and 34 sera from age-/sex-matched healthy controls using 
surface-enhanced laser desorption/ionization time-of-flight 
mass spectrometry (SELDI-TOF-MS) and identified 9 serum 
DEPs (7 upregulated and 2 downregulated) with both 82.4% sen-
sitivity and specificity in discrimination of NFPAs from controls. 
Another study (14) quantitatively compared 65 sera from PAs 
and 90 sera from healthy controls using proteomic fingerprint 
technology that was magnetic beads-based MALDI-TOF-MS 
TABLe 1 | Biological systems that operate in pituitary adenomas.
Systems DePs (n = 56) (3) DeGs (n = 128) (56)
(A) Hormones
(1) GH Somatotropin GHRH receptor
(2) TSH TSH β
(3) PRL Prolactin PRL
(4) LH LH β
(5) FSH FSH β
(B) Signal 
transduction
(1) G proteinsa G0 subunits 1, 2a G protein
G-binding protein
Regulator of G-protein 
signaling 16
Regulator of G-protein 
bind signaling 2, 5
Rho-GTPase-activating 
protein 5
(2) Cytokine receptors
(a) IGF IGF binding IGF
IGF binding
IGF binding 5
IGF binding 3
Protease Ser 11 IGF 
binding
(b) IL Splice isoform IL-15
(c) EGF EGF-containing fibulin 
ECM protein 1
(d) TGF TGFα receptor III
(e) IFN Interferon-induced 
protein 56
(3) Signal-system 
enzymes
MAPK 4
Phospholipase A2-IB
Protein kinase cAMP-
dependent β
(4) Retinoic acid Cellular retinoic acid-
binding protein 2
(5) Phosphorylation Ser/Thr protein 
phosphatase 2A
(6) Others Rab GDP dissociation 
inhibitor α
SH3-domain GRB2-like 2
XIST nuclear receptor 1, 3
(C) Reactive-oxygen 
species
(1) Cytochrome P450 Cytochrome P450, III A
(2) HSP HSP27 HSP 105 kDa
(3) GST GSTμ-2
(4) Peroxidase Phospholipid-
hydroperoxide glutathione 
peroxidase
(D) DNA/mRNA 
methylationa
6N-adenosine 
methyltransferasea
RNA-binding protein 2
Eukaryotic translation 
initiation factor 3–5
U4/U6-associated RNA 
splicing factor
(e) Tumor genes
(1) Protooncogenesa Protooncogene Tyr protein 
kinase FYNa
L-myc-1 protooncogene 
protein
(2) Oncogenes Neuroblastoma 
overexpressed gene
(Continued)
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and identified 42  m/z peaks that were significantly related to 
PAs (14). A three-biomarker diagnostic model was established 
with 90.0% sensitivity and 88.3% specificity in discrimination 
of human PAs from controls, which provided a powerful and 
reliable method to diagnose a PA (14).
Protein Antibody Array Analysis of PAs
Protein antibody array is an effective method to detect alterations 
of known proteins in PAs and easily translated to biomarkers 
for prediction, diagnosis, and prognostic assessment of PAs. A 
protein antibody array with 1005 monoclonal antibodies (54) 
identified 316 proteins in GH-, ACTH-, and PRL-secreting FPAs, 
and in NFPAs. Also, a set of DEPs were identified and confirmed 
using immunohistochemistry and Western blotting.
Proteomic Data-Based Pathway Networks 
in NFPAs
Each protein functions in the corresponding pathway–network 
system to exert its biological roles. The IPA pathway analysis is a 
widely used pathway analysis system to identify statistically sig-
nificant signaling pathway networks from a set of qualitative and 
quantitative proteomic data (22), including 111 proteins from a 
human NFPA tissue, 56 DEPs from human NFPA tissues and from 
prolactinoma tissues, 9 nitroproteins and 3 nitroprotein–protein 
complexes from a human NFPA tissue, and 8 nitroproteins from a 
pituitary control tissue. Comprehensive analysis of these pathway 
networks revealed four signaling pathway–network systems in 
NFPAs, including mitochondrial dysfunction, oxidative stress, 
cell-cycle dysregulation, and MAPK-signaling abnormality (22). 
These data provided potential biomarkers and contributed to the 
development of new efficacious treatment targets for PAs.
CLiNiCAL ReLevANCe OF PA 
PROTeOMiCS DATA
A great methodological progress of PA proteomics and use of 
proteomics approach to study pathophysiological characteristics 
of PAs have been reviewed, as described above. Here, the clini-
cal relevance of PA proteomics data (3, 6, 10–12, 55) is further 
addressed in the following aspects.
 (i)  Insights into molecular mechanisms of PAs. Proteomics 
offers a unique insight into molecular mechanisms of pitui-
tary tumorigenesis at the level of proteome. Our multiple 
comparative proteomics studies have confirmed our initial 
hypothesis that the proteome differs between PAs and 
controls (3, 10), between invasive and non-invasive PAs (6, 
11), and among different types of PAs (12); many DEPs and 
molecular networks were related to transcriptomics data (3, 
10, 36, 56) and to the corresponding biological systems (6, 
12, 22). These DEPs and molecular networks provided a 
basis to determine alterations in multiple protein systems 
that contribute to pituitary tumorigenesis. A set of DEP 
data (3) and DEG data (56) were correlated and obtained 
many protein systems that connect some critical aspects of 
PA formation (Table 1). First, the alterations in endocrine 
Systems DePs (n = 56) (3) DeGs (n = 128) (56)
(3) Tumor suppressor 
genes
Tumor rejection antigen 
(endoplasmin)
(F) excitatory 
(tachykinins)
Secretagogin Reticulocalbin l, EF-hand 
calcium-binding domain
Peptidylglycine 
α-amidating 
monooxygenase
(G) energy ATP synthase, 
mitochondrial
ATPase
ATP-binding protein
(H) immune system Ig κ, λ IgG
Pre-B cell leukemia 
transcription factor 3
CD58
MHC class 1
(i) intermediate 
filaments
Vimentin Vimentin
(J) Transcription 
factors
Pit 1
Basic transcription 
factor 3
(K) Cell cycle 
(G1-S-G2-M)
Death-associated protein
Folate receptor C1
aPublication data indicated that G protein (57), methylation (58), c-myc (59), PTTG, 
gsp, ccnd1 (59), FGF (76), Men-1, Prop-1, c-jun, Fos, and angiogenesis were related 
to pituitary adenomas.
DEPs, differentially expressed proteins; DEGs, differentially expressed genes.
Modified from Zhan et al. (55), with permission from Elsevier Science Publisher, 
copyright 2007.
TABLe 1 | Continued
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stresses are significantly associated with multiple cancer 
pathogenesis. Proteomics DEP data (3) demonstrate that 
some reactive-oxygen species (ROS)-related proteins are 
changed in PAs, including cytochrome P450, heat shock 
protein, GST, and phospholipid-hydroperoxide glutathione 
peroxidase. Fourth, DNA methylation was found to partici-
pate in pituitary tumorigenesis (58); proteomics study (3) 
revealed a methylation-related DEP (Table  1), and three 
methylation-related DEGs were found by transcriptom-
ics study (56). Fifth, oncogene activation in PAs (such as 
c-Myc) was found (59); protooncogene-related DEPs (3) 
and -related DEGs were found (56) (Table 1). Furthermore, 
multiple proteomics data-based molecular network stud-
ies revealed four important pathway–network systems 
that were altered in NFPAs, including mitochondrial 
dysfunction, oxidative stress, cell-cycle dysregulation, and 
MAPK-signaling system abnormality (22); and the last 
three pathway–network systems were involved in protein 
tyrosine nitration, for example, NRF2-mediated oxidative 
stress response, cell-cycle G2/M DNA damage checkpoint 
regulation, and p38 MAPK signaling were identified 
from PA nitroproteomic data (22). It shows that tyrosine 
nitration is involved in pituitary tumorigenesis. Finally, 
invasiveness of PAs is a challenging clinical problem. Fifty-
seven DEPs (30 upregulated and 27 downregulated) were 
found by proteomic study to associate the invasive features 
of PAs (6), and invasiveness-related pathway networks were 
found including MAPK-signaling abnormality, mitochon-
drial dysfunction, oxidative stress, proteolysis abnormality, 
ketogenesis and ketolysis, TR/RXR activation, CDK5 
signaling abnormality, and amyloid processing (6). These 
data demonstrate an overview of multiple protein systems 
that are involved in the pathogenesis of PAs.
 (ii) Discovery of potential biomarkers and therapeutic targets 
for PAs. DEPs and DEGs (Table 1) (3, 56) and the consist-
ently altered DEPs and DEGs in the levels of protein and 
mRNA (Table 2) (3, 10), which were identified with prot-
eomics and transcriptomics studies, are a part of our novel 
source of candidate biomarkers and therapeutic targets. 
Secretagogin was taken, for example (60). Secretagogin 
is a type of Langerhans-specific Ca2+-binding protein 
(61) and is highly expressed in the secretory neurons of 
the anterior pituitary (62). Secretagogin can inhibit the 
transcription of excitatory amino acid substance P (SP) 
to lower the growth rate of RIN-5F tumor cells (61), 
which is consistent with Desiderio’s hypothesis that an 
imbalance between inhibitory (opioid) and excitatory 
(tachykinin) neuropeptidergic systems might contribute 
to the pathogenesis of a pituitary macroadenoma (63–67). 
Proteomics and transcriptomics analyses (60) revealed 
a significant downregulation of secretagogin in a set of 
human NFPAs, and its protein expression was significantly 
related to its mRNA expression. These data demonstrate 
that secretagogin might be a biomarker for PAs. Moreover, 
other candidate biomarkers, such as G proteins, tissue 
transglutaminase, isocitrate dehydrogenase (NADP) 
cytoplasmic (IDH1), calreticulin, cytokine receptors, and 
hormone levels are the significantly clinical characteristics 
of PAs. Many pituitary hormones were found to change, 
including GH, TSH, PRL, LH, and FSH. The synthesis and 
secretion of each hormone are the important function of 
pituitary organ and are closely regulated by various sign-
aling pathways and factors. The cGMP-dependent PKA 
and nitric oxide are taken, for example, that significantly 
regulates water-soluble hormones. Proteomics study (20) 
discovered that the cGMP-dependent PKA 2 was nitrated 
in human pituitary tissues, which indicates that the nitra-
tion of cGMP-dependent PKA might be involved in the 
signal processing of water-soluble hormones. Second, the 
alterations in signal transduction systems significantly par-
ticipate in the pathogenesis of PAs. Many signal pathways 
were found by omics data to change, including G proteins, 
cytokine receptors (IFG, IL, EGF, TGF, and IFN), and some 
signal system-regulated enzymes (MAPK4, phospholipase 
A2-IB, and cAMP-dependent PKA). G proteins have been 
confirmed to play an important role in PAs (57), and FGF 
family members are involved in pituitary pathogenesis 
(58). FGF receptor genes mediate FGF signal pathways, 
and these genes encode receptor tyrosine kinases. Our 
proteomic DEP data clearly have a Tyr PKA. In addition, 
phosphorylation is significantly involved in signal path-
ways, and a Ser/Thr protein phosphatase 2A was found 
in our proteomics data (3). Third, oxidative/nitrative 
TABLe 2 | Genes that altered consistently in the levels of protein and mRNA with comparison of proteomics data and transcriptomic data.
DePs DeGs
Swiss-prot Protein name NF PRL Genbank Gene name NF PRL
O76038 Secretagogin (SCGN) − − (weak) NM_006998 SCGN: secretagogin −
P16520 Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) β-subunit 3
+ M31328 Guanine nucleotide-binding protein 
(G protein), β polypeptide
+
P21980 Tissue transglutaminase (TGM2) − − NM_004613 TGM2: transglutaminase 2 − −
O75874 Isocitrate dehydrogenase (NADP) 
cytoplasmic (IDH1)
+ + (weak) NM_005896 IDH1: isocitrate dehydrogenase 
(NADP+), soluble
+
P27797 Calreticulin precursor + AI807225 KDEL endoplasmic reticulum (ER) 
protein
+
P01241 Somatotropin (GH1) − − NM_000515 GH1: growth hormone 1 − −
NM_002059 GH2: growth hormone 2 − −
NM_000823 GHRHR: growth hormone releasing 
hormone receptor
− −
P01236 Prolactin (PRL) − ± NM_000948 PRL: prolactin − ±
P29373 Cellular retinoic acid-binding protein II + M97815 Cellular retinoic acid-binding protein 2 +
gi1066765 Hemoglobin β chain (HBB) − − NM_000518 HBB: hemoglobin β − −
NM_000519 HBD: hemoglobin δ −
The bracket after the protein name refers to its corresponding gene name.
NF, non-functional pituitary adenoma; PRL, hyperprolactinoma; +, upregulated in pituitary adenomas relative to controls; −, downregulated in pituitary adenomas relative to controls.
Reproduced from Zhan and Desiderio (1), with permission from Wiley-VCH, copyright 2005.
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ROS-related proteins (Tables 1 and 2), need to be further 
studied for potential biomarkers and therapeutic targets.
 (iii) Pituitary hormone variants/isoforms and PTMs in human 
PAs. Protein variants/isoforms result from splicing, PTMs, 
etc. The alterations in neuroendocrine hormone levels are 
the important characteristics of PAs. Proteomics studies 
demonstrate that human pituitary hormones had multi-
ple variants/isoforms. Not all of variants/isoforms were 
associated with PAs (3). First, GH variants/isoforms and 
PTMs. Somatotropin was significantly downregulated at 
the mRNA and protein levels in NFPAs (3) and in prolac-
tinomas (10), which was consistent with their monoclonal 
composition in origin (68, 69) – a NFPA generated from 
gonadotrophs and a prolactinoma from lactotrophs, 
whereas GH receptor gene was unchanged. These data 
showed that GH hyposecretion in NFPAs results from the 
hypoexpression of the GH gene. However, the interesting 
finding is that multiple GH variants/isoforms (17 spots 
contain somatotropin) were detected (3, 10); these data 
cannot be interpreted by transcriptomics method. The 
downregulated ratio of different GH isoforms was differ-
ent in each cell type of PA relative to controls. These data 
suggested that the proportion of different GH isoforms 
changed in each cell type adenoma compared to controls. 
Other researchers showed that the proportion of the circu-
lating GH isoforms significantly changed in PAs and other 
pituitary diseases (48, 49). The proportional change in the 
different GH isoforms might have an important value in 
the clinical evaluation of human PAs. Recently, we found 
that GH isoforms were derived from various splicing 
variants and PTMs, including phosphorylation. The phos-
phorylation of endogenous GH in the human pituitary 
(18) provided us with new insights into the mechanisms 
of GH that participates in the neuroendocrine signal 
pathways. Second, PRL variants/isoforms and PTMs. 
PRL is another important pituitary hormone. Proteomics 
detected six PRL variants/isoforms (3, 10). Similar to 
GH, each PRL variant/isoform was downregulated in 
each cell type of NFPA, with a different downregulated 
ratio relative to controls. There was no significant expres-
sion change in the PRL gene at the mRNA and protein 
levels in the prolactinomas relative to controls, which is 
consistent with a prolactinoma’s monoclonal composition 
in origin. However, the proportion of six PRL variants/
isoforms was changed in prolactinomas compared to 
controls. Other researchers showed that glycosylation 
was an important PRL modification (70) that produces 
different variants/isoforms; glycosylation of human PRL 
might downregulate its hormone bioactivity and promote 
its metabolic clearance (71). Other studies showed that the 
main variant of PRL was non-glycosylated form of PRL in 
human prolactinomas (72), which is consistent with our 
result that some PRL isoforms (10) were downregulated 
in prolactinomas relative to controls. Thus, we speculated 
that PRL variants/isoforms in these downregulated spots 
were possibly glycosylated PRL. Therefore, our detailed 
study of different variants/isoforms and PTMs of GH and 
PRL could lead to new insights into the clinical importance 
of pituitary hormones in a PA. The ratio of the change of 
each variant/isoform in human pituitary tissue has value 
for clinical research. However, one must realize that stud-
ies regarding protein variants/isoforms and PTMs are 
much insufficient in the width and depth in PAs, much 
more efforts should be made to insight into this area in a 
PA proteome because protein variants/isoforms and PTMs 
play very essential roles in tumor pathogenesis and could 
be potential biomarkers and therapeutic targets (44).
 (iv) Use of proteomic variations for personalized and precise 
medicine practice of PAs. We addressed in detail how to 
use proteomic variations for prediction, prevention, and 
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personalized medicine in NFPAs (73) and use the inte-
grated omics data for personalized and precise treatment 
for PAs with view point of multi-parameter systematic 
strategy (74, 75). Although there is a long distance to 
reach the extreme goal of personalized and precise 
medicine of PAs, proteomic variations in combination 
with integrated omic variations and the development of 
novel technologies offer the great promise to achieve the 
goal (73–75).
FUTURe PeRSPeCTiveS iN PA 
PROTeOMiCS
Although a great progress has been achieved in human PA 
proteomics, a series of unsolved issues are still existing in the 
following aspects. (i) High-throughput quantitative proteomics 
based on LCM-purified PA and control cells. LCM can effectively 
purify the PA cells and the corresponding pituitary cells for 
protein mapping analysis (8, 9) and minimize the inconsistency 
in cell types between PA tissues and postmortem pituitary control 
tissues. However, high-throughput quantitative proteomics strat-
egies, such as isobaric tags for relative and absolute quantification 
(iTRAQ) (77, 78), label-free strategies (79, 80), or sequential win-
dow acquisition of all theoretical spectra (SWATH) (81, 82), have 
not been used to determine DEPs between LCM-purified PA cells 
and the corresponding control cells (somatotroph, corticotroph, 
lactrotroph, gonadotroph, and tyrotroph) for more accurate 
understanding of molecular mechanisms of different cell types of 
PAs and discovery of reliable biomarkers. (ii) PTM-quantitative 
proteomics in PAs. PTMs are very important aspects in a pro-
teome (44). However, PTM proteomics studies in PAs are much 
insufficient in depth and width. Currently, only 28 phosphopro-
teins from pituitary control tissues (17, 18), 8 nitroproteins from 
a pituitary control tissue (20, 53), and 9 nitroproteins from an 
NFPA tissue (21) have been identified. PTM-quantitative prot-
eomics (such as iTRAQ- and label-free strategies) has not been 
performed to discover PA-related PTMs, such as phosphorylation 
(83, 84), nitration (19, 52), acetylation (85, 86), glycosylation (87, 
88), methylation (89), ubiquitylation (90), sumoylation (91), and 
succinylation (92); however, it is a very promising area in the 
field of PA proteomics. (iii) Structural proteomics of PAs. Three-
dimensional (3D) structure of a protein determines its biological 
significance in a PA biological system (52). If 3D structure of a key 
PA protein can be reconstructed with X-ray crystallography data, 
then it would easily interpret its biological roles and is possible 
to design a small-molecule drug toward that 3D structure for the 
development of effective therapy strategy for PAs. (iv) Body fluid 
proteomics/peptidomics of PAs. PA is a whole-body disease with 
multiple factors, multiple processes, and multiple consequences 
(74). Body fluid, such as CSF and serum, is the window for 
prediction, diagnosis, and prognostic assessment of a PA (73). 
Body fluid proteomics/peptidomics is barely performed and is 
very promising research direction for PAs, especially NFPAs. (v) 
Omics data-based systems biology and molecular networks. PA 
is a complicated whole-body disease with alterations in multiple 
molecules in the levels of genome, transcriptome, proteome, 
and metabolome; and these molecules are mutually associated 
within a molecular network system (75). Multiple omics data-
based systems biology and molecular network analyses might 
discover key molecular networks that are common or specific 
to different types of PAs and benefit discovery of effective and 
reliable biomarkers. (vi) Invasive mechanisms and biomarkers of 
FPAs and NFPAs. Proteomics studies regarding invasive charac-
teristics of PAs analyzed only invasive and non-invasive NFPAs 
with 2DGE-quantiative proteomics (6, 11). Because of 2DGE 
disadvantages, further non-gel high-throughput quantitative 
proteomics is needed (26). Moreover, this type of study should 
expand to invasive and non-invase FPAs. The clarification of 
invasive mechanisms and determination of biomarkers might 
benefit management of invasive PAs. (vii) Heterogeneity of NFPAs. 
NFPA is highly heterogeneous. Current proteomics study focused 
only on NF−-, LH+-, FSH+-, and LH/FSH+-NFPA subtypes with 
2DGE-quantitative proteomics (12). It should expand to other 
NFPA subtypes, such as silent corticotroph adenoma and silent 
somatotroph adenoma. Moreover, current proteomics studies of 
PAs mainly focused on NFPAs (1, 3, 6, 12), but barely analyzed 
FPAs (10). Therefore, in future, more efforts toward research on 
FPAs with proteomics strategies are required. The clarification of 
proteomic variations in different types of NFPAs and FPAs would 
benefit complete understanding of molecular mechanisms and 
discovery of biomarkers that are common and specific to different 
types of PAs and really realize personalized and precise medicine 
practice of PAs.
CONCLUSiON
The use of proteomics to clarify molecular mechanisms of PAs 
and discover reliable biomarkers for prediction, prevention, 
and personalized treatment for PAs is our long-term goal. A 
great progress has been achieved in the field of PA proteomics 
in the past 10 years, including sample preparation with LCM 
and 2D-LC–MS/MS (8, 9), significant extension of proteomic 
reference mapping data in PAs and controls (8, 9, 29–31), 
proteomics analyses of invasive characteristics (6, 11), tumor 
heterogeneity (12), protein variants/isoforms (3, 10, 15, 16) and 
PTMs (17–21), and serum proteomics and peptidomics (13, 14) 
of PAs, protein antibody array analysis of PAs (54), and prot-
eomic data-based pathway networks in NFPAs (22). These new 
progresses of pituitary proteomics are encouraging and provide 
new promise for insight into pathophysiological system of PAs. 
However, there are many aspects that have not been resolved 
and are worth studying in-depth including high-throughput 
quantitative proteomics based on LCM-enriched pituitary cells, 
PTM-quantitative proteomics, structural proteomics, body 
fluid proteomics and peptidomics, omics data-based integrative 
molecular networks, and proteomic characteristics of invasive-
ness and heterogeneity of PAs. Furthermore, one must realize 
that, although clinical relevance of PA proteomics data was 
discussed in this article, the real functional analysis regarding 
most of these interesting proteins from PA proteomics studies 
has not been carried out in the PA biological systems, which 
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is very important aspect in the post-proteomics and must be 
strengthened in future. Resolving all these aspects will benefit 
systematical and complete understanding of PA pathogenesis 
and management of PAs toward personalized and precise 
medicine practice.
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